|Videos|June 15, 2022
A US-Based, Injectables-Focused CDMO with Available Capacity and End-to-End Capabilities
Author(s)August Bioservices
Ryan Downey, Director of Customer Operations, outlines August Bioservices’ capabilities for its customers and what it means to work with them.
- They focus on sterile injectables in multiple container sizes from vials to syringes to flexible IV bags— coupled with an analytical services department.
- The current CDMO market is constrained for those who need the capacity to start their innovative work, which is where August Bioservices comes in.
- With robust tools and a strong team, they can solve difficult challenges with formulation, commercial configuration, the timing of a project, and analytical characterizations.
Related Content
Trending on Pharmaceutical Technology
1
Danish Biotechs Attracting Investor Attention
2
Pharma's AI ROI Problem Isn't a Tech Problem but a Qualification Problem
3
BMS Bets on Flexible Capacity With $2.3B Texas Campus
4
Why the Orzeyful Approval Matters Beyond One Drug Class
5